Leading Edge Urology: 47th Duke Urologic Assembly and Duke Urologic Cancer Symposium
With over eight decades of experience in caring for patients with urologic diseases, Duke’s Division of Urologic Surgery has established itself as a world leader in urologic care, research, and education. The Duke Urologic Assembly began in the 1970’s and was held annually at Pinehurst; we are excited to return to our roots at Pinehurst for the first time in decades. LEADING EDGE UROLOGY: 47th Annual Duke Urologic Assembly will evaluate the most recent advances in the diagnostic evaluations, therapeutic options, management of complications, and technologies that provide leading edge care to patients. Participants will be engaged through moderated discussions and interactive lectures on the latest evidence-based approaches to managing a wide range of urologic conditions across the spectrum of life.
In partnership with our colleagues in the Duke Cancer Institute we will designate Thursday of the DUA for the DUKE UROLOGIC CANCER SYMPOSIUM; a full day CME event featuring lectures by Duke and guest Medical Oncologists, Radiation Oncologists, and Urologists speaking on the latest diagnostic, medical, and surgical aspects of urologic cancer management.
Total available credits: 19.5
- Thursday – March 5 - 4.5
- Friday, March 6 - 5.25
- Saturday, March 7 - 5.75
- Sunday, March 8 - 4
- Enumerate systemic therapies for management of renal cell carcinoma, including newer agents.
- Review advances in the detection of urothelial carcinoma and perioperative care of patients undergoing surgery.
- Incorporate newer strategies of radiation therapy into the management of prostate cancer.
- Identify advances in robotic surgical techniques for renal cell carcinoma and prostate cancer.
- Address population approaches and the economic impact in the treatment of prostate cancer.
- Cite various controversies in prostate cancer screening.
- Recognize the role of the urologist in cancer survivorship.
- Gain greater proficiency in correct coding for urologists and identify ways to avoid claim denials and loss of revenue.
- Incorporate advances in imaging of GU malignancies and trauma into clinical practice.
- Describe new AUA guidelines for management of cryptorchidism.
- Incorporate better surgical and post-surgical care of nephrolithiasis for improved patient outcomes.
- Propose treatment therapies in the care of the geriatric patient as it impacts urologic interventions.
- Describe management options for urinary retention due to underactive bladder.
- 19.50 AMA PRA Category 1 Credit(s)™
- 19.50 Attendance